Interview at AAPS 2014 with Pharmaceutical Outsourcing
Summary: Todd Stutzman and John Essex discuss Catalent’s OptiPact™ Technology, capabilities for Orphan Drugs, Catalent’s factors of differentiation and the challenges faced by innovator companies.